Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: An open-label, budesonide-controlled, randomized study

Medical Science Monitor

Volumn 12, Issue 6, 2006, Pages

  Tursi, Antonio ^a,e   Giorgetti, Gian Marco ^b   Brandimarte, Giovanni ^c   Elisei, Walter ^c   Aiello, Fabio ^d  

^a Lorenzo Bonomo Hospital   (Italy)

^b S EUGENIO HOSPITAL   (Italy)

^c Cristo Re Hospital   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e NONE   (Italy)

Author keywords

Beclomethasone diproprionate; Budesonide; Crohn's disease; Treatment

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DEPRESSION; DISEASE CLASSIFICATION; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; MENSTRUATION DISORDER; NAUSEA; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BECLOMETHASONE; BUDESONIDE; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 33744964650     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Keighley MR, Stockbrugger RW: Inflammatory bowel disease. Aliment Pharmacol Ther, 2003;18(Suppl.3): 66-70
2. Campieri M: New steroids and new salicylates in inflammatory bowel disease: a critical reappraisal. Gut, 2002; 50(Suppl.III): iii43-iii46
3. Greenberg GR, Feagan BG, Martin F et al: Oral budesonide for active Crohn's disease. N Engl J Med, 1994; 331: 836-41
4. Michetti P, Juillerat P, Mottet C et al: Therapy of mild to moderate luminal Crohn's disease. Digestion, 2005; 71: 13-18
5. Rizzello F, Gionchetti P, D'Arienzo A et al: Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther, 2002; 16: 1109-16
6. rd April 1992. Int J Pharmaceutics, 1994; 112: 199-206
7. Kornbluth A, Salomon P, Sachard DB: Crohn's Disease. In: Sleisenger MH, Fordtrand JS, eds. Gastrointestinal Disease, 5th ed. Philadelphia: WB Saunders, 1993: 1270-304
8. Best WR, Becktel JM, Singleton JW, Kearn F: Development of Crohn's disease activity index: national cooperative Crohn's disease study. Gastroenterology, 1976; 70: 439-44
9. Guyatt G, Mitchell A, Irvine EJ et al: A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology, 1989; 96: 804-10
10. Summers RW, Switz DM, Session JT Jr et al: National Cooperative Crohn's Disease study: results of drug treatment. Gastroenterology, 1979; 77: 847-69
11. Malchow H, Ewe K, Brandes JW et al: European Cooperative Crohn's Disease study (ECDS): results of drug treatment. Gastroenterology, 1984; 86: 249-66
12. Reshef R, Varkel J, Shiller M, Loberant N: Systemic effects of rectally administered corticosteroid. Isr J Med Sci, 1992; 28: 98-100
13. Østergaard Thomsen O, Cortot A, Jewell D et al: A comparison of budesonide and mesalamine for active Crohn's disease. N Eng J Med, 1998; 339: 370-74
14. Otley A, Steinhart A, Otley A: Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev, 2005; 19: CD000296
15. Campieri M, Adamo S, Valpiani D et al: Oral beclometasone dipropionate and left-sided active ulcerative colitis: a multicentre randomised study. Aliment pharmacol Ther, 2003; 17: 1471-80
16. Van Der Heide H, Van Den Brandt-Gradel V, Tytgat GNJ et al: Comparison of beclometasone diproprionate and prednisolone 21-phosphate enemas in the treatment of ulcerative proctitis. J Clin Gastroenterol, 1988; 10: 169-72
17. Brattsand R: Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol, 1990; 4: 407-14